INCY Knows JAK Incyte Pharmaceuticals (INCY) is an MTSL recommendation and one of the few stocks that trades below its BUY LIMIT. In our February 15 update (Issue #748), we suggested that the Q4:12 quarterly report was a pivotal turning point for the company; and the stock subsequently had begun to make its move and[…]
To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.